Navigation Links
Drug Patent Compulsory Licensing

Penn State researcher argues that ambiguous international rules outlining when and how governments may "break" pharmaceutical patents may end up significantly reducing incentives for innovation while at the same time failing to increase access to medicines.

In a new paper "Confronting Myths and Myopia on the Road from Doha," Daniel Cahoy, associate professor of business law at Penn State's Smeal College of Business, argues that the problem is a lack of clarity in compensation for patent owners.

He suggests that a three-tiered approach to compulsory license remuneration based on a country's individual ability to pay would do much to resolve the predicament.

Current international law "has few limitations on which countries can 'break' patents simply to control costs, what circumstances create a necessary condition, or even what level of remuneration is required," Cahoy writes. As a result, relatively wealthy nations may receive unintended windfalls while least developed countries may continue to struggle for access.

Under complex World Trade Organization rules, governments are permitted to issue patent compulsory licenses, which allow countries to manufacture cheaper versions of patented pharmaceuticals for non-commercial use or in cases of health care emergencies.

Just recently, Brazil and Thailand have invoked these rules simply to lower the cost of expensive AIDS and heart medications-a strategy that Cahoy argues should be more controlled. In his paper, Cahoy identifies three myths that have typically obscured workable remuneration rules:

Myth No. 1: Equitable compulsory licenses must offer savings from the market. Cahoy argues that it is possible for patent holders to be compensated at market prices even when compulsory licenses are invoked. At the very least, he writes, market compensation should be integrated into the debate.

Myth No. 2: Pharmaceutical companies shoul d be indifferent to compulsory licensing so long as "reasonable" remuneration is available.

Compulsory licensing supporters say that pharmaceutical companies should be satisfied with payments that allow them to break even or turn a small profit, but Cahoy argues that the equity in such a payment scheme is far more elusive than many suggest.

Myth No. 3: Antitrust compulsory licenses provide a reliable royalty benchmark. Cahoy argues that the low royalties attached to remedial compulsory licenses for antitrust violations should not be used to set remuneration levels in non-punitive cases in which the patentee has done nothing wrong.

Taking these myths into account, Cahoy's proposed licensing regime keeps innovation incentives intact, but also ensures that developing countries have access to pharmaceuticals.

During public health crises, he argues for a three-tiered arrangement, in which remuneration is based on the economic status of the country issuing the compulsory license. Industrialized nations will be required to pay full market price, even during a pandemic.

Developing countries would be allowed a limited free ride, with royalties based on the individual country's ability pay. Finally, the world's least developed countries would be granted the ability to issue royalty-free compulsory licenses during health emergencies.

In cases outside of a public health crisis or antitrust violations, Cahoy's approach establishes full market compensation as the default policy for every country. He also identifies the adoption of a national exhaustion rule, which would limit importation into non-licensing countries, and manufacturing limits as important elements to any new compensation system.

But, regardless of the approach that is ultimately adopted, Cahoy argues that "a revision of essential international law is required to both better enable access and shore up innovation ince ntives. "Considering the problem in terms of remuneration rather than the legal right to license, one can arrive at clearer, more equitable solutions," he concludes.


Related medicine news :

1. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
2. HIV Patients Opposes Patenting Of AIDS Drug
3. Provigil Patent Extension Accorded To Cephalon
4. AIDS Sufferers Protest against Proposed Patent for Tenofovir
5. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
6. Venus Remedies Files 5th International Patent Application
7. US Court Rules Against Lupin in Ramipril Patent Case
8. Patent for Seminal RNAi innovation Cleared in Australia
9. Canada: On Popular Demand, Tamiflu finds a Berth in the Directory of Patent Drugs
10. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
11. A Patented Device for Rapid Diagnosis of Diseases
Post Your Comments:

(Date:11/30/2015)... , ... November 30, 2015 , ... ... has verified that their Vasont Universal Integrator (VUI) extension unites with Syncro Soft’s ... and managing content as a continuous process with the latest release of oXygen® ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. and ... Mesh technology for soft tissue repair in the US via Insightra’s national direct ... surgical mesh intended to support and reinforce soft tissue for 6-9 months before ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... of the assets of DataTrade Solutions Inc., a Healthcare IT consulting, development and ... utilizing the programming and technical experience available within DataTrade to extend the services ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... Laser Center is one of a select few plastic surgeons in the New ... fat removal. , SculpSure™ is the world’s first heat-induced laser treatment for fat ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... of critical importance to the medical schools of the future. To reach an ... suite at the 2015 ChangeMedEd conference in Chicago, organized by the American Medical ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , November 30, 2015 ... directed at up to 10 G protein-coupled receptor (GPCR) ... ) to research and develop potential new medicines directed ... across multiple therapeutic areas. --> Heptares Therapeutics ... company and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; ...
(Date:11/30/2015)... Mexico Healthcare and Life Sciences Report 2015 . ... --> Pharmaboardroom releases its new 98-page Mexico Healthcare and ... , a country of over 122 million people. --> ... people. --> It offers companies, investors, policymakers, and stakeholders ... the second largest pharma and healthcare market in Latin ...
(Date:11/30/2015)... and REHOVOT, Israel , Nov. ... pharmaceutical company focused on acquiring and developing innovative therapies ... the appointment of Keith A. Katkin as ... Gregory J. Flesher , chief executive officer for OticPharma, ... successful organizations.  As chairman, he will be able to ...
Breaking Medicine Technology: